medRxiv preprint doi: https://doi.org/10.1101/2023.09.19.23295793; this version posted September 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# 1 Metabolic traits and the risk of head and neck cancer:

# 2 a systematic review and meta-analysis

- 3
- 4 Alexander J Gormley <sup>1,2\*</sup>, Charlotte Richards <sup>3\*</sup>, Francesca Spiga <sup>4,5</sup>, Alex Whitmarsh <sup>4</sup>, Emily
- 5 Gray<sup>2</sup>, Jo Hooper<sup>6</sup>, Barry G Main<sup>1,2</sup>, Emma E Vincent<sup>4,5,7</sup>, Rebecca C Richmond<sup>4,5</sup>, Julian PT
- 6 Higgins <sup>4,5</sup>, Mark Gormley <sup>1,2,4,5</sup>
- 7
- 8 <sup>1</sup> Bristol Dental School, Faculty of Health Sciences, University of Bristol
- 9 <sup>2</sup> Bristol Dental Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
- 10 <sup>3</sup> School of Dentistry, Cardiff University
- <sup>4</sup> Population Health Sciences, Bristol Medical School, University of Bristol
- <sup>5</sup> MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
- 13 University of Bristol
- <sup>6</sup> Library and information services, University Hospitals Bristol and Weston NHS Foundation
- 15 Trust
- <sup>7</sup> School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol
- 17 \* Joint first authors
- 18
- 19 Corresponding author
- 20 Email: <u>mark.gormley@bristol.ac.uk</u>
- 21
- 22
- 23
- 24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 25 Abstract

26

#### 27 Introduction

28

29 The overall incidence of head and neck cancer (HNC) continues to rise, despite a decline in 30 smoking rates, particularly within developed countries. Obesity and related metabolic traits 31 have been attributed to a growth in cancer rate, so further exploration of these risk factors is warranted in HNC. A comprehensive systematic review and meta-analysis was conducted 32 33 in order to obtain the most precise observational estimates between metabolic trait 34 exposures and risk of HNC.

35

#### Methods 36

37

38 A search strategy was developed with an information and content specialists. Multiple 39 databases including Cochrane Library, OVID SP versions of Medline, EMBASE, pre-prints and 40 the grey literature were searched. The primary outcome for included studies was incident 41 HNC and exposures included obesity defined by body mass index (BMI), type 2 diabetes, 42 dyslipidaemia, and hypertension, using pre-specified definitions. A combined risk effect 43 across studies was calculated using both fixed and random-effects meta-analysis. Heterogeneity was assessed between studies using the Cochrans Q and I<sup>2</sup> statistical tests. 44 45 The ROBINS-E preliminary tool was used to assess the bias in each included result.

46

#### 47 Results

48

49 The search generated 7,316 abstracts, of these 197 full text articles were assessed for 50 eligibility and 36 were included for full qualitative and quantitative synthesis. In the analysis 51 of 5 studies investigating the association between obesity and incidence of HNC, there was 52 an overall RR of 1.06 (95%CI (0.76, 1.49), P heterogeneity <0.024, I<sup>2</sup>= 73.2%) using a 53 random-effects model. 6 studies reported on the association between type 2 diabetes and incidence of HNC, with an overall RR of 1.13 (95%CI (0.95, 1.34), P heterogeneity= <0.0001, 54 55  $I^2$  = 80.0%) using a random-effects model. An increased risk of hypertension was consistent 56 across HNC subsites, with the strongest association found in the larynx (RR= 1.17, 95%CI

57	(1.10, 1.25), P heterogeneity= 0.186, I <sup>2</sup> = 37.7%). For dyslipidaemia, only 2 studies were
58	available for meta-analysis in the laryngeal subsite, with some evidence of an increased risk
59	association of both low high-density lipoprotein (RR= 1.12, 95%CI (1.07, 1.18), P
60	heterogeneity= 0.103, I <sup>2</sup> = 62.5%) and high triglyceride levels (RR= 1.10, 95%CI (1.05, 1.15), P
61	heterogeneity= 0.319, I <sup>2</sup> = 0.0%)) using random-effects models. Over 80% of studies were
62	judged to be at Very High or High risk of bias using the ROBINS-E tool.
63	
64	Conclusion
65	
66	Despite individual studies suggesting an association between BMI and HNC, limited effect
67	was demonstrated in this meta-analysis. There was evidence of an association between
68	hypertension and dyslipidaemia on incident HNC, however caution is required due to the
69	high levels of heterogeneity recorded in these studies. Observational associations are
70	susceptible to confounding, bias and reverse causality so these results must be interpreted
71	with caution. Future work should include meta-analysing studies separately by geographic
72	region, as this appears to be a clear source of heterogeneity.
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	

#### 89 Introduction

90

91 Despite the significant reduction in smoking <sup>1</sup>, particularly in developed countries, the overall incidence of head and neck cancer (HNC) continues to rise <sup>2,3</sup>. Given this potentially 92 changing aetiology <sup>4</sup>, further exploration of other risk factors is warranted to enhance 93 94 prevention strategies. According to the World Health Organization (WHO), at least 40% of 95 all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors <sup>5</sup>. The growth in cancer 96 97 attributable to metabolic risk is increasing, with a global attributable fraction due to high 98 body mass index (BMI) at around 3.6%, equating to almost half a million new cases each 99 year <sup>67</sup>. Public health strategies have been unsuccessful in addressing the current obesity 100 epidemic at the population level, which could also result in more overall cancer cases in the vears to come<sup>8</sup>. It has been projected that obesity could even supersede smoking as the 101 102 primary driver of cancer in the coming decades <sup>5</sup>.

103

104 People living with obesity and associated metabolic traits have an increased risk of 105 developing cancer <sup>5</sup>, but the epidemiological evidence surrounding HNC is not conclusive 106 <sup>9,10</sup>. In the largest pooled analysis, obesity defined by higher BMI was associated with a 107 protective effect for HNC in current smokers (hazard ratio (HR)= 0.76, 95%CI (0.71, 0.82), p < 0.0001, per 5 kg/m<sup>2</sup>) and conversely, a higher risk in never smokers (HR= 1.15, 95%CI 108 (1.06, 1.24) per 5 kg/m<sup>2</sup>, p < 0.001)<sup>11</sup>. More recent cohort studies have failed to show a clear 109 association between BMI and HNC<sup>12-16</sup>. Similarly, a meta-analysis of observational studies 110 investigating type 2 diabetes with oral and oropharyngeal subsites found an increased risk 111 112 ratio (RR) of 1.15, 95%CI (1.02, 1.29)<sup>17</sup>. This finding has been supported by more recent independent cohorts <sup>12,18-20</sup>. Lastly, hypertension (raised systolic blood pressure (SBP) or 113 114 diastolic blood pressure (DBP)), has been correlated with head and neck cancer risk across multiple studies <sup>19-23</sup>. There are a number of proposed mechanisms linking these metabolic 115 traits and cancer, with none specifically linked to HNC. In short, hyperglycaemia may 116 117 provide a substrate for tumour growth or lead to direct DNA mutation. Insulin itself is a potent growth factor, thought to promote proliferation and carcinogenesis both directly and 118 119 indirectly through insulin like growth factor-1 (IGF-1)<sup>24-26</sup>. Insulin resistance can lead to a 120 chronic proinflammatory environment and the formation of macrophages which produce

121	mutagenic agents and reactive oxygen species leading to DNA damage <sup>27</sup> . Any underlying
122	mechanism between hypertension and cancer risk remains unknown <sup>23</sup> . Lipids are an
123	essential component of the cell wall and so increased cellular uptake of cholesterol has
124	been seen in many cancers, while other malignancies have demonstrated lipid metabolism
125	reprogramming which can help promote a cancer cell phenotype including proliferation,
126	differentiation and metastasis <sup>28</sup> .
127	
128	We aimed to conduct the largest, most comprehensive systematic review and meta-analysis
129	to date, in order to obtain the most precise observational association between metabolic
130	traits and risk of HNC. If available, results were stratified by subsite (i.e., oral cavity,
131	oropharynx, hypopharynx, and larynx), with pre-defined subgroup analyses performed to
132	enhance interpretation, and additional sensitivity analysis to improve certainty in the
133	results.
134	
135	Methods
136	
137	Research Question
138	'Do metabolic traits affect the risk of developing head and neck cancer?'
139	
140	Eligibility criteria
141	Population- participants over 18 years old, of either sex, from any country or ethnic
142	background.
143	Exposures- 1) obesity, 2) type 2 diabetes, 3) hypertension and 4) dyslipidaemia as defined in
144	the study protocol below. These will be collectively described as metabolic traits.
145	<b>Comparison-</b> participants who have not been diagnosed with a metabolic trait(s).
146	Outcome- incident head and neck squamous cell carcinoma (HNC).
147	
148	Study Selection
149	We focused on prospective observational studies reporting the risk of metabolic traits on
150	incident HNC. This was to ensure a direct temporal relationship between the exposure and
151	onset of head and neck cancer. Eligibility criteria are detailed in <b>Table 1</b> .
152	

#### 153 Data sources and search strategy

- 154 A systematic search strategy (Supplementary Table 1) was formulated by clinicians,
- 155 scientific researchers and a specialist librarian for Head & Neck Surgery and Medicine.
- 156 Medical Subject Headings (MeSH) and keywords were iteratively combined with the
- 157 Boolean operators AND, OR and NOT. Multiple databases were searched from January 1966
- November 2021, including OVID SP versions of Medline and EMBASE, using the formulated 158
- 159 search strategy (Supplementary Table 1). Pre-print servers medRxiv (since June 2019) and
- 160 BioRxiv (since November 2013) were also searched. In addition, the following electronic
- 161 bibliographic databases were comprehensively searched: EThOS, Google Scholar, Open Grey
- 162 and ClinicalTrials.gov, to identify articles from the grey literature and conference
- 163 proceedings using a modified search strategy (Supplementary Table 2). References
- 164 extracted from the full-length articles were reviewed to identify other publications of
- 165 interest. Duplicate articles were removed using Covidence (Covidence systematic review
- 166 *software*, Veritas Health Innovation, Melbourne, Australia)<sup>29</sup>.
- 167
- 168 Table 1. Study selection criteria
- 169

Inclusion criteria	Exclusion criteria
• All studies published between January 1966 and November 2021, in the English language.	<ul> <li>The study is not based on incident head and neck squamous cell carcinoma, or contains only prevalent data, meaning a temporal relationship cannot be</li> </ul>
<ul> <li>Human participants &gt;18 years old, of either sex or any ethnic background.</li> </ul>	inferred e.g., case-control.
5	• Studies focused on cancer survival or progression.
• Observational (e.g., cohort studies) reporting the risk of	of
incident head and neck squamous cell carcinoma.	<ul> <li>Studies with no original data or effect statistic reported. Continuous results to be discounted if they</li> </ul>
<ul> <li>Studies must have original data and report an adjusted odds ratios, risk ratio, hazard ratio (HR), or standardize incidence ratios (SIR) with their 95% CIs (or data to</li> </ul>	d cannot be interpreted/ converted into categorical ed e.g., BMI >30.
calculate them).	<ul> <li>Human studies only, no <i>in vivo</i> animal or <i>in vitro</i> cell line studies.</li> </ul>
• Exposures: obesity, type 2 diabetes, hypertension, and	l
dyslipidaemia, with definitions as described in the stud protocol.	<ul> <li>Studies of head and neck epithelial dysplasia, potentially malignant disease, or carcinoma <i>in situ</i>.</li> </ul>
<ul> <li>Outcome: head and neck cancer (HNC) diagnosis in a major subsite i.e., oral cavity, oropharynx, larynx or hypopharynx, which may be human papilloma virus (HPV) positive or negative.</li> </ul>	<ul> <li>Squamous cell carcinoma of other sites e.g., nasopharynx, salivary gland, oesophagus, skin, or lung due to differing aetiology, histological subtypes, and risk factors e.g., Epstein Barr Virus.</li> </ul>

To ensure transparent and reproducible methodology, this study has been reported in line 171

172 with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

173 statement and was pre-registered on International Prospective Register of Systematic

174 Reviews (PROSPERO) in 2021 (CRD42021250520). The protocol was also accepted for

- publication in *BMJ Open*<sup>30</sup>. 175
- 176

Data screening and extraction 177

178 All titles and abstracts were initially screened by two authors (A.G. and C.R.) using

Covidence <sup>29</sup>. Any conflicts were resolved by a third independent reviewer (M.G). A PRISMA 179

180 flowchart <sup>31</sup> representing the study selection process is shown in **Figure 1**. Full text of

181 articles included after title and abstract screening were retrieved and screened by (A.G., C.R

182 and M.G.). Data were then extracted from articles which met the inclusion criteria (Table 1).

183 This was performed independently by three authors (E.G., C.R and M.G.) using a

184 standardised data collection spreadsheet containing: study ID; the first author's last name,

185 year of publication, study design, sample size, age and sex of the subjects, country of origin,

186 duration of follow-up in cohort studies, assessment of exposure and outcome, adjusted

187 covariates, number of cases, the effect estimates with 95%CIs and follow-up duration. From

each study, risk estimates were extracted which reflected the greatest degree of 188

189 adjustments for potential confounders. If study data appeared in more than one article, the

190 most recent publication or largest e.g., pooled result were extracted for the statistical

191 analysis.



206	2) The WHO defines type 2 diabetes as a chronic disease that occurs when the body cannot
207	effectively use the insulin it produces and is largely the result of excess body weight and
208	physical inactivity. Diagnosis was defined as symptoms such as polyuria or polydipsia, plus
209	36,37.
210	<ul> <li>a random blood plasma glucose concentration ≥ 11.1 mmol/l or;</li> </ul>
211	<ul> <li>a fasting plasma glucose concentration ≥ 7.0 mmol/l (whole blood ≥ 6.1 mmol/l) or;</li> </ul>
212	<ul> <li>two-hour plasma glucose concentration ≥ 11.1 mmol/l two hours after 75g</li> </ul>
213	anhydrous glucose in an oral glucose tolerance test (OGTT) or;
214	<ul> <li>glycated haemoglobin (HbA1c) 6.5% or more (48 mmol/mol and above)</li> </ul>
215	A diagnosis of type 2 diabetes via self-report, International Classification of Diseases (ICD)
216	codes or medical records was also accepted.
217	
218	3) The WHO definition of hypertension as <sup>38</sup> :
219	<ul> <li>a systolic blood pressure (SBP) reading of ≥130 mmHg; and/or</li> </ul>
220	<ul> <li>a diastolic blood pressure (DBP) readings on both days of ≥85 mmHg.</li> </ul>
221	ICD-codes and patients taking antihypertensive medication were also acceptable diagnoses.
222	
223	4) Dyslipidaemia classified as serum total cholesterol (TC), low density lipoprotein
224	cholesterol (LDL-C), triglycerides, apolipoprotein B, or lipoprotein(a) concentrations above
225	the 90 <sup>th</sup> percentile, or high density lipoprotein cholesterol (HDL-C) or apolipoprotein
226	concentrations below the $10^{th}$ percentile for the general population in which the study was
227	conducted <sup>39</sup> . ICD-codes and patients taking cholesterol-lowering medication were also
228	acceptable diagnoses.
229	
230	Outcome definitions
231	All diagnoses of incident head and neck squamous cell carcinoma should have been
232	confirmed using histology by a trained pathologist and reported using appropriate ICD codes
233	<sup>40</sup> . Cancer cases for the disease of interest have the following ICD-10 codes: oral cavity
234	(C02.0 – C02.9, C03.0 – C03.9, C04.0 – C04.9, C05.0 – C06.9) oropharynx (C01.9, C02.4,
235	C09.0 – C10.9), hypopharynx (C13.0 – C13.9), overlapping (C14 and combination of other

sites) and 25 cases with unknown ICD code (other). Older versions of ICD code e.g., ICD-8and 9 were also accepted.

238

### 239 Quality assessment of studies

240 This assessment was used in evaluating the strength of evidence from the included studies. 241 Three authors (A.G., C.R. and M.G.) independently assessed papers for risk of bias during 242 data extraction using the Risk of Bias in Non-randomised Studies – of Exposures (ROBINS-E) tool (available at: <u>https://www.riskofbias.info/welcome/robins-e-tool</u>)<sup>41</sup>. The ROBINS-E tool 243 244 aims to assess the result of interest in an observational study for risk of bias, where that 245 study is designed to assess the effect of exposure on outcome <sup>42</sup>. Pre-defined confounding 246 variables that were agreed, included: age, sex, smoking status, alcohol intake, ethnicity, and 247 socio-economic status. Further confounding variables that were recognised as important, 248 but possibly to a lesser extent, included: dietary intake, physical exercise, and other 249 metabolic traits (e.g., where BMI was the exposure, adjusting for hypertension, 250 dyslipidaemia, and type 2 diabetes). The 'appropriateness' of each study to address the 251 review question was also considered.

252

Data visualisations of the ROBINS-E tool were created using the *robvis* tool (available at:
<u>https://mcguinlu.shinyapps.io/robvis/</u>). An individual panel has been developed for each
individual exposure. Individual results from each included study were assessed using the
tool for each included study. There was no difference in risk of bias assessment within each
study and therefore the overall risk of bias assessment is presented below.

258

## 259 Data analysis and synthesis

260 The analysis and synthesis process were performed in two phases. The first phase consisted 261 of estimating the effect of each metabolic trait (obesity, type 2 diabetes, dyslipidaemia, and 262 hypertension) on incident HNC separately for each included study. All included studies were cohort studies, with most using non-exposed comparisons and reporting risk (RR) and 263 264 hazard ratios (HR). Other studies using external general population comparisons reported 265 standardised incidence ratios (SIR). Because the absolute risk of HNC is low, all the above measures yield similar estimates of RR and this approach has been taken previously in 266 267 similar head and neck cancer meta-analyses <sup>17</sup>. The second phase focussed on estimating

the combined effect across studies using meta-analysis, using *metan* software in Stata
(*Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC). Summary effects
with their corresponding 95%CIs were derived using the method described by DerSimonian
and Laird for both fixed effects and random effects models, which incorporates betweenstudy variability <sup>43</sup>. This was performed separately for each metabolic trait, with a
preference for random-effects if there is no important difference between the two
methods.

275

276 The analysis yielded information about the heterogeneity of effects across studies, using 277 Cochran's Q test and Higgins' I<sup>2</sup> statistic. To further explore the sources of heterogeneity, 278 subgroup, and meta-regression analyses were performed according to age, geographic 279 location, year of publication, methods of exposure assessment, length of follow-up, the 280 number of cancer cases and adjustment for confounding factors including age, sex, smoking 281 and alcohol use. Small study effects, which may reflect publication bias, study quality or 282 other sources of heterogeneity were assessed using funnel plots, which show effect 283 estimates from individual studies plotted against the standard error as a measure of each 284 study's size or precision. In the absence of bias and between study heterogeneity, the 285 scatter will be due to sampling variation alone, with the plot resembling a symmetrical 286 inverted funnel. Smaller studies will be scattered more widely at the bottom, with larger studies nearer the top and any gaps where smaller studies are missing will be evident <sup>44</sup>. 287 288 Sensitivity analyses were performed by excluding two large pooled analyses from the metaanalyses, one for BMI<sup>11</sup> and the other for type 2 diabetes <sup>17</sup>, and calculating an estimate for 289 the remainder of the studies to evaluate whether the results were significantly affected by 290 291 these studies.

292

### 293 Results

294

The search generated 7,316 potential records of which 6,129 were screened following the removal of 1,187 duplicates. Of these, 197 full-text articles of interest were assessed for eligibility. One hundred and sixty one of these articles were subsequently excluded: 105 due to study designs that could not infer a temporal relationship between the exposure and outcome, 29 where the exposure was not relevant or as defined above, 16 in which the

300 outcome was not relevant or as defined above, 1 with an ineligible comparison group 301 (diabetics treated versus not treated), 7 with no original data or reported effect statistic 302 (e.g., short abstracts), 2 studies had continuous data only which was not comparable and 1 303 article that was not written in English. The remaining 36 eligible articles were included for full qualitative and quantitative synthesis to investigate the association between metabolic 304 traits and HNC risk (Figure 1). One large pooled analysis for BMI <sup>11</sup> included the results from 305 4 of the studies <sup>45-48</sup> and similarly, a pooled analysis for type 2 diabetes<sup>17</sup> included the 306 results from 6 of the studies <sup>9,49-53</sup>, so only the two pooled analyses were represented in the 307 308 final **Table 2** and subsequent analyses.

- 309
- 310 Eight studies reported the association between BMI (n= 2,859 cases) and risk of HNC <sup>11,12,14-</sup>
- 311 <sup>16,54-56</sup>, with 15 studies reporting the association with type 2 diabetes (n= 17,582 cases) <sup>12,17-</sup>
- 312 <sup>20,23,24,57-64</sup>, six studies hypertension (n= 12,151 cases) <sup>12,19-23</sup>, and four studies dyslipidaemia
- 313 (n= 6,410 cases) <sup>12,19,20,65</sup> and HNC risk (**Table 2**). Adjustments were made for potential
- 314 confounders of two or more factors, including age, in all studies.
- 315

### 316 **Obesity and risk of HNC**

317 In the analysis of five studies investigating the association between obesity and incidence of

- 318 combined head and neck cancer sites, there was an overall RR of 1.06 (95%CI (0.76, 1.49))
- using a random-effects model, little evidence of an effect (Figure 2a). The result was similar
- when using a fixed-effects model (RR= 1.10, 95%CI (0.97, 1.25)). There was however
- 321 evidence for the presence of substantial heterogeneity between studies (*P* heterogeneity
- 322 <0.024, I<sup>2</sup>= 73.2%) (Figure 2a). With respect to individual subsites, there was again little
- evidence of an association of obesity on oral cavity (RR= 0.92, 95%CI (0.81, 1.04)),
- 324 oropharyngeal (RR= 1.05, 95%CI (0.69, 1.59)), or laryngeal (RR= 0.95, 95%CI (0.81, 1.11))
- 325 cancer using a random-effects model. There were similar results when using a fixed-effects
- 326 model (**Figure 2b d**).

First Author/ Year/	Study design	Sample size,	Exposure	Method of	Method of	Adjusted covariates	Outcome	Exposed	Reported	Effect	95% CI	Follow-
Country		age (years), sex		exposure	outcome		(subsite)	cases	Statistic	size		up
				assessment	assessment							(years)
Obesity												
Samanic/2006/	Prospective	N= 362,552	BMI > 30	Measured at	ICD-7 codes	age, smoking status, year	Larynx	17	RR	0.94	0.57 - 1.56	19
Sweden 54	cohort	Age (mean): 34		baseline								
		Male: 100%										
Bhaskaran/ 2013/ UK	Prospective	N= 5,243,978	BMI > 30 - 34.9	MR	ICD-10	age, sex	Oral cavity	1147	HR	0.81	0.63 - 1.03	6 (3-11)
55	cohort	Age (median,			codes							
		IQR): 38 (27-54)										
		Male: 45%										
			BMI > 35				Oral cavity	310		0.82	0.57 - 1.2	
Coudot / 2015 /USA 11*	Doolod analysis	N- 1 0/1 200	DMI >20	SP/ or mostured at	100 10	and can adjustion schort	Hoad and Nock	207	LID	1.40	1 00 1 01	<u>\</u> 1
Gaudet/ 2015/05A	POOleu analysis	N= 1,941,500	BIVII >30	bacalina	codos SP	age, sex, education, conort,	Field and Neck	297	пк	1.40	1.00-1.01	>1
		Age (mean). 55		Daseinie	Loues, Sh,	alconol, genetic ancestry	cancer combined					
		Male: 41%			IVIR, anu							
					state cancer							
					registries							
Maasland/ 2015/	Prospective	N= 3,980	BMI > 30	SR	ICD-9 codes	age, sex, cigarette smoking,	Head and Neck	11	RR	0.52	0.24 - 1.14	2-20.3
Netherlands 56	cohort	Age (mean, SD):				alcohol	cancer combined					
		61 (4)										
		Male: 49%										
							Oral cavity	6		0.76	0.28 - 2.04	
							Larynx	5		0.72	0.27 - 1.92	
Ward/ 2017/	Prospective	N= 363,094	BMI > 30	SR/ or measured at	ICD-10	age, sex, recruitment centre,	Oral cavity (male)	19	HR	1.12	0.58 - 2.13	15.1
European <sup>16</sup>	cohort	Age (range): 25-		baseline	codes	smoking status, alcohol,						
		70				education						
		Male: 35%										
							Oropharynx	14		0.69	0.36 - 1.30	
							(male)					

							Hypopharynx (male)	8		0.68	0.28 - 1.67	
							Larynx (male)	45		0.91	0.60 - 1.36	
			BMI >30				Oral cavity (female)	23		1.42	0.79 - 2.54	
							Oropharynx (female)	11		2.03	0.88 - 4.65	
							Hypopharynx (female)	0		NA	NA	
							Larynx (female)	4		0.6	0.20 - 1.85	
Gribsholt/ 2020/	Prospective	N= 313,321	BMI > 30	MR	ICD-8; ICD-	age, sex, year of diagnosis	Oropharynx	154	SIR	1.02	0.86 - 1.19	6.7
Denmark 15	cohort	Age (median):			10 codes							
		43										
		Male: 27%										
							Larynx	116		0.98	0.81 - 1.18	
							Oral cavity	100		0.93	0.76 - 1.13	
Cao/ 2020/ UK 14	Prospective	N= 390,575	BMI > 30	Measured at	ICD-10	age, sex, ethnicity, Townsend	Oral cavity	268	HR	1.02	0.74 - 1.40	7.8
	cohort	Age (mean, SD):		baseline	codes	deprivation index,						
		56 (8)				qualification, employment						
		Male: 47%				status, alcohol intake,						
						smoking status						

Jiang/ 2021/ UK 12	Prospective	N= 474,929	Central	Measured at	ICD-10	age, sex, education, ethnicity,	Head and Neck	304	HR	1.04	0.90 - 1.21	6.2 (+/-
	cohort	Age (mean, SD):	Obesity/ BMI	baseline	codes	index of multiple deprivation,	cancer combined					1.2)
		56 (8)	>30			alcohol consumption,						
		Male: 46%				smoking status, physical						
						activity, fruit, and vegetable						
						intake, NSAIDs use, CRP						
Type 2 Diabetes												
Chodick/ 2010/ Israel	Retrospective	N= 100,595	Diabetes	MR	ICD-9 codes	age, region, socioeconomic	Head and Neck	20	HR	0.90	0.54 - 1.48	8 (2.5)
57	cohort	Age (mean, SD):	mellitus			status, use of healthcare	cancer combined					
		62 (13)				services a year prior to index	(male)					
		Male: 53%				date, body mass index, history						
						of cardiovascular diseases						
							Head and Neck	8		0.61	0.28 - 1.27	
							cancer combined					
							(female)					
Atchison/ 2011/ USA	Prospective	N= 4,501,578	Diabetes	ICD-8 and ICD-9	ICD-8 and 9	smoking, alcohol, obesity via	Oral cavity (buccal	3036	RR	0.85	0.82 - 0.89	11.2
58	cohort	Age (median):	mellitus	codes	codes	surrogate variables	site)					
		55										
		Male: 100%										
							Larynx	1413		0.76	0.71 - 0.8	
Lo/ 2013/ Taiwan 59	Prospective	N= 1,790,868	Type 2 diabetes	ICD-9 codes/ MR	ICD-9	age, sex, urbanisation,	Head and Neck	3750	HR	1.21	1.13 - 1.30	3.5
	cohort	Age (mean, SD):	mellitus			hypertension, dyslipidaemia	cancer combined					
		61 (14)										
		Male: 49%										

Walker/ 2013/ (UK,	Prospective	N= 81,018	Type 2 diabetes	MR	ICD-10	age, socioeconomic status	Head and Neck	NA	HR	0.77	0.61 - 0.98	6
Scotland) 60	cohort	Age (range): 55-	mellitus		codes		cancer combined					
		79					(male)					
		Male: 45%										
							Head and Neck	NA	HR	0.90	0.60 - 1.34	
							cancer combined					
							(female)					
Nakamura/ 2013/	Prospective	N= 30,720	Type 2 diabetes	SR/ 214 cases	ICD-10	age, smoking status, body	Larynx (male)	4	HR	3.61	1.16 - 11.2	16
Japan 61	cohort	Age (mean, SD):	mellitus using	confirmed HbA1c	codes	mass index, physical						
		M= 54 (12) F=	cut-off of age	≥6.1% based on the		activity, length of education						
		56 (13)	>30 years	diagnostic criteria		in years, history of						
		Male: 46%		set by the Japan		hypertension, history of						
				Diabetes Society		stroke, history of ischemic						
				,		heart disease, total energy						
						intake, intake of fat,						
						ethanol, coffee						
						ethanol, coffee	Larynx (female)	NA		NA	NA	
						ethanol, coffee	Larynx (female)	NA		NA	NA	
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective	N= 9,884,228	Type 2 diabetes	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium,	Larynx (female) Oral cavity (male)	NA 2411	SIR	NA 1.09	NA 1.03 - 1.15	10
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective	N= 9,884,228 Age: >20	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male)	NA 2411	SIR	NA 1.09	NA 1.03 - 1.15	10
Lin/ 2014/ Taiwan 62	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male)	NA 2411	SIR	NA 1.09	NA 1.03 - 1.15	10
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male) Oral cavity	NA 2411 733	SIR	NA 1.09 1.08	NA 1.03 - 1.15 0.94 - 1.25	10
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male) Oral cavity (female)	NA 2411 733	SIR	NA 1.09 1.08	NA 1.03 - 1.15 0.94 - 1.25	10
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male) Oral cavity (female)	NA 2411 733	SIR	NA 1.09 1.08	NA 1.03 - 1.15 0.94 - 1.25	10
Lin/ 2014/ Taiwan <sup>62</sup>	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation	Larynx (female) Oral cavity (male) Oral cavity (female)	NA 2411 733	SIR	NA 1.09 1.08	NA 1.03 - 1.15 0.94 - 1.25	10
Lin/ 2014/ Taiwan <sup>62</sup> Tseng/ 2014/ Taiwan	Prospective cohort Prospective	N= 9,884,228 Age: >20 Male: 55% N= 89,089	Type 2 diabetes mellitus Type 2 diabetes	ICD-codes/ MR	ICD-9 codes	ethanol, coffee age, insurance premium, urbanisation age, sex, hypertension,	Larynx (female) Oral cavity (male) Oral cavity (female) Head and Neck	NA 2411 733 634	SIR	NA 1.09 1.08 1.48	NA 1.03 - 1.15 0.94 - 1.25 1.31 - 1.67	10
Lin/ 2014/ Taiwan <sup>62</sup> 52 Tseng/ 2014/ Taiwan	Prospective cohort Prospective cohort	N= 9,884,228 Age: >20 Male: 55% N= 89,089 Age (mean, SD):	Type 2 diabetes mellitus Type 2 diabetes mellitus	ICD-codes/ MR ICD-9 codes	ICD-9 codes ICD-9 codes and	ethanol, coffee age, insurance premium, urbanisation age, sex, hypertension, hyperlipidaemia, coronary	Larynx (female) Oral cavity (male) Oral cavity (female) Head and Neck cancer combined	NA 2411 733 634	SIR	NA 1.09 1.08 1.48	NA 1.03 - 1.15 0.94 - 1.25 1.31 - 1.67	10
Lin/ 2014/ Taiwan <sup>62</sup> Tseng/ 2014/ Taiwan	Prospective cohort Prospective cohort	N= 9,884,228 Age: >20 Male: 55% N= 89,089 Age (mean, SD): 55 (15)	Type 2 diabetes mellitus Type 2 diabetes mellitus	ICD-codes/ MR ICD-9 codes	ICD-9 codes ICD-9 codes and histologically	ethanol, coffee age, insurance premium, urbanisation age, sex, hypertension, hyperlipidaemia, coronary artery disease, chronic kidney	Larynx (female) Oral cavity (male) Oral cavity (female) Head and Neck cancer combined	NA 2411 733 634	SIR	NA 1.09 1.08 1.48	NA 1.03 - 1.15 0.94 - 1.25 1.31 - 1.67	10
Lin/ 2014/ Taiwan <sup>62</sup> Tseng/ 2014/ Taiwan 24	Prospective cohort Prospective cohort	N= 9,884,228 Age: >20 Male: 55% N= 89,089 Age (mean, SD): 55 (15) Male: 53%	Type 2 diabetes mellitus Type 2 diabetes mellitus	ICD-codes/ MR ICD-9 codes	ICD-9 codes ICD-9 codes and histologically confirmed	ethanol, coffee age, insurance premium, urbanisation age, sex, hypertension, hyperlipidaemia, coronary artery disease, chronic kidney	Larynx (female) Oral cavity (male) Oral cavity (female) Head and Neck cancer combined	NA 2411 733 634	SIR	NA 1.09 1.08 1.48	NA 1.03 - 1.15 0.94 - 1.25 1.31 - 1.67	10

						disease, obesity, geographic						
						region, monthly income						
							Oral cavity	362		1.74	1.47 - 2.06	
							Oropharynx	56		1.53	1.01 - 2.31	
							Larynx	44		1.03	0.68 - 1.56	
							Hypopharynx	58		0.99	0.69 - 2.89	
			<b>T O I I I I</b>		100 1 (							0.0.05
Gong/ 2015/	Pooled cohort	N= 5,535,615	Type 2 diabetes	MR/ SR	ICD-codes/	age, sex, calendar year, body	Oral cavity and	3002	RR	1.15	1.02 - 1.29	8.6-35
European 17*		Age (range): 30-	mellitus		MR	mass index, smoking, alcohol	oral-pharyngeal					
		71				use, district of residence,	cancer					
		Male: 46%				physical activity, NSAIDs use,						
						family history of cancer,						
						endoscopy history,						
						hypertension, ischaemic heart						
						disease, race, education,						
						marital status, health status,						
						dietary intake of red meat,						
						white meat, fruits, vegetables,						
						coffee, multivitamin use						
He/ 2018/ China 63	Retrospective	N= 793.795	Type 2 diabetes	MR	!CD-10	age, sex, comorbidities,	Head and Neck	35	HR	2.09	1.23 - 3.56	5
- <b>,,</b>	cohort	Age (mean, SD):	mellitus (new		codes	concomitant medication.	cancer combined					
		43 (15)	onset)			hospitallisations, cancer-						
		Male: 52%	,			related detection						
						examinations, number of						
						outpatient visits						
Saarela/ 2019/	Prospective	N= 428,326	Type 2 diabetes	MR	ICD-10	NA	Oral cavity	308	SIR	1.14	1.01 - 1.26	10.5
Finland <sup>18</sup>	cohort	Age: >30	mellitus		codes							
		Male: 48%										

						NA	Oropharynx	233		0.95	0.83 - 1.07	
						NA	Larynx	263		0.9	0.79 - 1.00	
Kim/ 2019/ Korea <sup>20</sup>	Prospective	N= 23,253,270	Type 2 diabetes	Fasting blood	ICD-codes	age, sex, smoking, alcohol,	Larynx	2608	RR	1.12	1.06 - 1.19	7
	cohort	Age (mean, SD):	mellitus	glucose measured		exercise						
		48 (14)		>100mg/dL								
		Male: 49%										
Qi/ 2019/ China 64	Retrospective	N= 410,191	Type 2 diabetes	MR	ICD-10	age, sex	Larynx	NA	SIR	0.95	0.65 - 1.25	3
	cohort	Age (mean, SD):	mellitus		codes							
		62 (14)										
		Male: 50%										
Seo/ 2020/ Korea <sup>23</sup>	Prospective	N= 9,746,606	Type 2 diabetes	Measured at	ICD-codes	age, sex, smoking status,	Oral cavity	320	HR	1.1	0.98 - 1.24	7
	cohort	Age (mean): 51	mellitus	baseline/ MR		alcohol intake, exercise, body						
		Male: 55%		prescription of		mass index						
				antidiabetic drugs								
							Larynx	160		1.2	1.02 - 1.42	
Jiang/ 2021/ UK 12	Prospective	N= 474,929	Type 2 diabetes	Fasting plasma	ICD-10	age, sex, education, ethnicity,	Head and Neck	174	HR	1.22	1.02 - 1.45	6.6 (1.2)
	cohort	Age (range): 37-	mellitus	glucose measured	codes	index of multiple deprivation,	cancer combined					
		73		>5.5mmol/L/ SR		alcohol consumption,						
		Male: 46%				smoking status, physical						
						activity, fruit, and vegetable						
						intake, NSAIDs use, CRP						
Kim/ 2021/ Korea <sup>19</sup>	Prospective	N= 6,757,048	Type 2 diabetes	Fasting blood	ICD-10	age, sex, smoking status,	Larynx	675	HR	1.25	1.12 - 1.40	6.4
	cohort	Age (mean, SD):	mellitus	glucose measured >	codes	alcohol intake, exercise, body						
		49 (13)		100 mg/dL or the		mass index						

		Male: 43%		use of								
				hypoglycaemic								
				agent								
Hypertension												
Stocks/ 2012/	Prospective	N= 577,799	Hypertension	Measured at	ICD-7 codes	age, sex, stratified by cohort,	Oral cavity and	561	HR	1.31	1.15 - 1.48	12
European <sup>21</sup>	cohort	Age (mean): 44		baseline (increased		body mass index, smoking	Oropharynx					
		Male: 50%		blood pressure per			(male)					
				10mmHg)								
							Oral cavity and	177	HR	1.05	0.85 - 1.28	
							Oropharynx					
							(female)					
Kim/ 2019/ Korea 20	Prospective	N= 23,253,270	Hypertension	Measured at	ICD-codes	age, sex, smoking, alcohol,	Larynx	3565	HR	1.12	1.06 -1.19	7
	cohort	Age (mean, SD):		baseline SBP >130		exercise						
		48 (14)		or DBP >85mmHg								
		Male: 49										
Christakoudi/ 2020/	Prospective	N= 307,318	Hypertension	Measured at	ICD-codes	age, sex, body mass index,	Head and Neck	382	HR	1.21	1.03 - 1.42	13.7 (4.4)
European <sup>22</sup>	cohort	Age (mean, SD):		baseline		diabetes mellitus, education,	cancer combined					
		53		SBP ≥140 mmHg, or		physical activity, smoking						
		Male: 37%		DBP ≥90 mmHg/		status, alcohol intake, fruit						
				SR		consumption, vegetable						
						consumption, red meat						
						consumption						
							Oral cavity and	180		1.15	0.91 - 1.45	
							Oropharynx					
							Larynx	142		1.37	1.04 - 1.80	

Seo/ 2020/ Korea <sup>23</sup>	Prospective	N= 9,746,606	Hypertension	Measured at	ICD-codes	age, sex, smoking status,	Oral cavity	2535	HR	1.11	1.04 - 1.17	7
	cohort	Age (mean): 51		baseline SBP >140	via	alcohol intake, exercise, body						
		Male: 55%		or DBP >90mmHg	insurance	mass index, diabetes mellitus						
					system							
							Larynx	1301		1.23	1.13 - 1.33	
Jiang/ 2021/ UK 12	Prospective	N= 474,929	Hypertension	Measured at	ICD-10	age, sex, education, ethnicity,	Head and Neck	160	HR	1.00	0.82 - 1.20	6.5
	cohort	Age (range): 37-		baseline SBP >130	codes	index of multiple deprivation,	cancer combined					
		73		or DBP >85mmHg/		alcohol consumption,						
		Male: 46%		SR on treatment		smoking status, physical						
				with		activity, fruit, and vegetable						
				antihypertensives		intake, NSAIDs use, CRP						
Kim/ 2021/ Korea <sup>19</sup>	Prospective	N= 6,757,048	Hypertension	Measured at	ICD-10	age, sex, smoking status,	Larynx	681	HR	1.16	1.04 - 1.30	6.4
	cohort	Age (mean): 49		baseline SBP >130	codes	alcohol intake, exercise, body						
		Male: 43%		or DBP >85mmHg/		mass index						
				SR on treatment								
				with								
				antihypertensives								
Dyslipidaemia												
Chyou/ 1992/ Hawaii	Prospective	N= 7 716	Serum	Measured serum	ICD-8 codes	age smoking alcohol	Oral cavity and	6	RR	0.52	0 19 - 1 44	22
65	cohort	Age-adjusted	cholesterol	cholesterol (mg/dl)		age, smoking, aconor	Oronharvny	0		0.52	0.13 1.11	
	conort	Male: 100%	(200-234  mg/dl)				oropharynx					
		Wale: 100%	(200-234 mg/ul)									
			Serum				Oral cavity and	4	RR	0 38	0 12 - 1 26	
			cholesterol				Oronharvey	-		0.00	0.12 1.20	
			(225± mg/dl)									
			(2007 mg/ui)									

Kim/ 2019/ Korea 20	Prospective	N= 23,253,270	Low HDL	Measured HDL	ICD-10	age, sex, smoking, alcohol,	Larynx	1700	HR	1.09	1.03 - 1.15	7
	cohort	Age (mean, SD):	cholesterol	cholesterol <40	codes	exercise						
		48 (14)		mg/dL for men and								
		Male: 49%		<50 mg/dL for								
				women								
			High	Measured		age, sex, smoking, alcohol,	Larynx	2484	HR	1.09	1.04 - 1.15	
			triglyceride	triglyceride ≥ 150		exercise						
				mg/dL								
Jiang/ 2021/ UK 12	Prospective	N= 474,929	Low HDL	Measured HDL	ICD-10	age, sex, education, ethnicity,	Head and Neck	464	HR	1.01	0.84 - 1.22	6.5
	cohort	Age (range): 37-	cholesterol	<1.0mmol/L for men	codes	index of multiple deprivation,	cancer combined					
		73		and <1.30mmol/L		alcohol consumption,						
		Male: 46%		for women		smoking status, physical						
						activity, fruit, and vegetable						
						intake, NSAIDs use, CRP						
			High	Measured at			Head and Neck	665	HR	0.95	0.81 - 1.10	
			triglyceride	baseline			cancer combined					
				>1.7mmol/L/ or SR								
				on treatment with								
				cholesterol-lowering								
				medications								
Kim/ 2021/ Korea 19	Prospective	N= 6.757.048	High	Measured	ICD-10	age, sex, smoking status.	Larvnx	653	HR	1.16	1.04 - 1.30	6.4
	cohort	Age (mean): 49	triglyceride	triglyceride ≥ 150	codes	alcohol intake, exercise, body	,					
		Male: 43%	0,	mg/dL		mass index						
			Low HDL	Measured HDL			Larvnx	434	HR	1.15	1.02 - 1.29	
			cholesterol	cholesterol <40			- /					
				mg/dL for men and								

### <50 mg/dL for

women

### 327

 Table 2. Descriptive characteristics of studies of metabolic traits and risk of head and neck 308er

- 329
- 330 Key: SR, self-report; MR, medical report; ICD, International Classification of Disease codes; RR, risk ratio; HR, Hazard ratio; SIR, standardised incidence ratio; BMI, body mass
- 331 *index; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; SES, socio-economic status.*
- 332
- \* Pooled analyses Gaudet et al. includes effect estimates for Andreotti et al. (2010),<sup>45</sup> Gaudet et al. (2012),<sup>46</sup> Hashibe et al. (2013),<sup>47</sup> Etemadi et al. (2014).<sup>48</sup>
- \* Pooled analysis for Gong et al. includes effect estimates for Hjalgrim et al. (1997),<sup>49</sup> Wideroff et al. (1997),<sup>50</sup> Stocks et al. (2009),<sup>51</sup> Wotton et al. (2011),<sup>9</sup> Tseng et al.
- 335 (2013),<sup>52</sup> Lai et al. (2013).<sup>53</sup>

#### 336 Figure 2. Relative risks for the association between obesity and incidence of head and neck cancer

### 337 combined and by subsite



368 Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model. medRxiv preprint doi: https://doi.org/10.1101/2023.09.19.23295793; this version posted September 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 369

## 370 Type 2 diabetes mellitus and risk of HNC

- 371 In the analysis of 6 studies on the association between type 2 diabetes and incidence of 372 combined head and neck cancer, there was an overall RR of 1.13 (95%CI (0.95, 1.34)) using a 373 random-effects model. Strong evidence of heterogeneity was present between studies (P heterogeneity= <0.0001, I<sup>2</sup>= 80.0%) (Figure 3a). There was a trend towards an increased risk 374 375 association with oral cavity (RR= 1.13, 95%CI (0.97, 1.31)), oropharyngeal (RR= 1.16, 95%CI (0.73, 1.83)) and laryngeal (RR= 1.05, 95%CI (0.87, 1.26)) cancer using a random effects 376 377 model, but again all results crossed the null, with strong evidence of heterogeneity across all 378 subsites (Figure 3b – d). When using a fixed effects model, the result for combined head and 379 neck cancer sites showed a stronger increased risk effect (RR= 1.22, 95%CI (1.16, 1.29)), but attenuated towards the null in the individual subsites. 380
- 381

Figure 3. Relative risks for the association between type 2 diabetes mellitus and incidence of head
and neck cancer combined and by subsite



medRxiv preprint doi: https://doi.org/10.1101/2023.09.19.23295793; this version posted September 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

393



- **396** Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model.
- 397

### 398 Hypertension and risk of HNC

- 399 In the analysis of only 2 studies on the association between hypertension and incidence of
- 400 combined head and neck cancer, there was limited evidence of an increased risk (RR= 1.11,
- 401 95%CI (0.92, 1.33)) using a random-effects model. There was evidence of substantial
- 402 heterogeneity among studies (*P* heterogeneity= 0.134, I<sup>2</sup>= 55.6%) (Figure 4a). An increased
- 403 risk of hypertension was consistent across HNC subsites, with a RR of 1.16 (95%CI (1.05,
- 404 1.28)) found for combined oral cavity and oropharyngeal cancer, and the strongest effect
- 405 found in the larynx (RR= 1.17, 95%Cl (1.10, 1.25)) (Figure 4b c). The amount of
- 406 heterogeneity was similar in both oral cavity and oropharyngeal combined (P
- 407 heterogeneity= 0.108, I<sup>2</sup>= 50.6%) and laryngeal cancer analyses (*P* heterogeneity= 0.186, I<sup>2</sup>=
- 408 37.7%). The results remained similar when using a fixed effects model across all sites.

#### 410 Figure 4. Relative risks for the association between hypertension and incidence of head and neck

#### 411 cancer combined and by subsite

							Risk R	atio	% Weight,	
а.	Study	Ν		Head a	nd neck cancer c	combined	(95% (	CI)	DI	L
	Chrietakoudi 2020	307318			1		1 21 (1	03 1 42)	53 75	
	Jiang 2021	474929			_		1.00 (0	0.83, 1.21)	46.25	
	Overall, DL	782247					1.11 (0	).92, 1.33)	100.00	l
	Overall, IV				ŏ		1.12 (0	).99, 1.26)		
	(l² = 55.6%, p = 0.134)				~					
	<u>e</u>	1								
10		.125	.25	.5	1	2	4			

412

						Risk Ratio	% Weight,
b.	Study	Ν		Oral cav	vity and oropharynx combined	(95% CI)	DL
	Stocks 2012 (males)	288899				1.31 (1.15, 1.49)	27.67
	Stocks 2012 (females)	288899				1.05 (0.86, 1.29)	15.68
	Christakoudi 2020	307318			<b>+</b> *-	1.15 (0.91, 1.45)	13.00
	Seo 2020	9746606			-	1.11 (1.05, 1.18)	43.64
	Overall, DL	10631722			$\Diamond$	1.16 (1.05, 1.28)	100.00
	Overall, IV				$\diamond$	1.14 (1.08, 1.20)	
	(l <sup>2</sup> = 50.6%, p = 0.108)						
		l .125	.25	l .5	1 2	1 4	
413							

						Risk Ratio	% Weight,
c.	Study	Ν		La	arynx	(95% CI)	DL
					1		
	Kim 2019	23253270			-	1.12 (1.06, 1.19)	42.81
	Christakoudi 2020	307318				1.37 (1.04, 1.80)	4.73
	Seo 2020	9746606				1.23 (1.13, 1.33)	31.27
	Kim 2021	6757048			+	1.16 (1.04, 1.30)	21.19
	Overall, DL	40064242			$\diamond$	1.17 (1.10, 1.25)	100.00
	Overall, IV				$\diamond$	1.16 (1.11, 1.21)	
	(l <sup>2</sup> = 37.7%, p = 0.186)						
	2	125	25	5		1	

414

415 *Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model.* 

416

### **Dyslipidaemia and risk of HNC** 417

- 418 There were only 2 studies available for meta-analysis, both investigating the effect of
- 419 dyslipidaemia on incident laryngeal cancer risk. There was some evidence of an increased

- risk association of both low HDL (RR= 1.12, 95%CI (1.07, 1.18)) and high triglyceride levels 420
- 421 (RR= 1.10, 95%CI (1.05, 1.15)) using a random-effects model (Error! Not a valid bookmark
- 422 self-reference.  $\mathbf{a} - \mathbf{b}$ ). In the low HDL analysis, there was evidence of moderate
- 423 heterogeneity (*P* heterogeneity= 0.103,  $I^2 = 62.5\%$ ), which was not found in the high
- triglycerides analysis (P heterogeneity= 0.319, I<sup>2</sup>= 0.0%) (Error! Not a valid bookmark self-424
- reference.a b). The results remained similar when using a fixed effects model across all 425
- sites. These findings were not supported in the single study by Jiang et al.<sup>12</sup> which 426
- 427 investigated low HDL (RR= 1.01, 95%CI (0.84, 1.22)) and high triglycerides (RR= 0.95, 95%CI
- 428 (0.81, 1.10)) on head and neck combined cancer (Table 2).
- 429
- 430 Figure 5. Relative risks for the association between dyslipidaemia and incidence of laryngeal cancer



- 438 weighted fixed-effects model.
- 439
- 440

441

#### Subgroup analyses 442

443 Pre-defined subgroup meta-analyses were conducted for all four metabolic traits according 444 to age, geographic location, year of publication, methods of exposure assessment, risk of 445 bias score, length of follow-up, the number of cancer cases and adjustment for confounding 446 factors including age, sex, smoking and alcohol use (Supplementary Table 3).

447

448 Stratifying by geographic location of the study resulted in a difference for both obesity

449 (European (RR= 0.97, 95%CI (0.90, 1.04)) vs USA (RR= 1.40, 95%CI (1.08, 1.81), P difference=

450 0.007), type 2 diabetes (Asian (RR= 1.23, 95%CI (1.13, 1.33)) vs European (RR= 1.00, 95%CI

451 (0.90, 1.12)) vs USA (RR= 0.81, 95%CI (0.72, 0.90), P difference <0.0001) and dyslipidaemia

452 (Asian (RR= 1.12, 95%CI (1.08, 1.16) vs European (RR= 0.97, 95%CI (0.87, 1.10) vs USA (RR=

453 0.45, 95%CI (0.21, 0.98), P difference= 0.006). Various methods of exposure assessment did

454 result in a differences for both obesity and type 2 diabetes. Within obesity, there were

455 differences between the use of medical records (RR= 0.94, 95%CI (0.86, 1.04) vs self-report

456 (RR= 0.63, 95%CI (0.38, 1.06)) vs measurements taken at baseline (RR= 1.02, 95%CI (0.91,

457 1.15)) vs a combination of the aforementioned methods (RR= 1.40, 95%CI (1.08, 1.81)) (P

458 difference = 0.011).

459

When stratifying by year of publication (before or after 2010), by adjustment for 460

461 confounding factors, length of follow-up and number of cancer cases, this resulted in

differences only within dyslipidaemia. However, there was only one small study by Chyou et 462

al. (1992)<sup>65</sup> representing the before 2010, no adjustment, >10 year follow-up and <50 463

464 cancer cases categories which is of high risk of bias.

465

466 Risk of bias assessment

Risk of bias assessment was undertaken using the Risk of Bias In Non-randomized Studies -467 of Exposure (ROBINS-E) tool <sup>42</sup>. From all included studies, each result (n= 85) included in the 468 469 meta-analysis was individually risk assessed across the seven domains of bias, accounting 470 for confounding variables which were pre-defined as important (i.e., age, sex, smoking 471 status, alcohol intake, ethnicity, and socio-economic status). There was no difference 472 between individual results within each study, therefore the overall study ratings only are

presented in Supplementary Figures 1 – 4. One study was rated as 'Very high' risk of bias 473 474 (3.7%) <sup>18</sup>, 21 studies were rated as 'High' (77.8%) <sup>15-17,19-24,54-65</sup>, one study as 'Some concerns' (3.7%) <sup>66</sup> and the remaining studies as 'Low' (14.8%) <sup>12,14</sup>. All 'High' and 'Very high' ratings 475 476 were due to bias that arose due to inadequate adjustment for confounding and/or the 477 handling of missing data. 478 Funnel plots for each metabolic trait were used to assess asymmetry which may be as a 479

480 result of true heterogeneity, poor methodological quality in smaller studies, reporting or publication bias <sup>44</sup>. For obesity, there appeared to be only limited asymmetry, with only one 481 outlier by Gaudet et al.<sup>11</sup> and potential smaller studies missing from the bottom right corner 482 483 (Figure 6a). For type 2 diabetes mellitus, there were significantly more larger studies, many 484 of which lay outside the 95%CI suggesting the presence of heterogeneity. There were eight 485 results from several studies which appear to be outliers in the type 2 diabetes funnel plot, including results from Atchison et al. <sup>58</sup>, Lo et al. <sup>59</sup>, Tseng et al. <sup>24</sup>, Lin et al. <sup>62</sup>, and Kim et al. 486 487 <sup>19,20</sup>. Four out of five of these outlier studies were distinct in that they were conducted in 488 Asian only populations (Figure 6b). There were too few ( $\leq 10$ ) studies for hypertension and 489 dyslipidaemia) to confidently distinguish true asymmetry (Figure 6c-d).

- 490
- 491

Figure 6. Funnel plots showing effect estimates for metabolic traits on overall head and neck cancer 492 risk (all subsites)

493

501



### b. Type 2 diabetes mellitus



.5

Studies

### 502



511 Key: Estimated  $\theta_{IV}$  (red) line is centred on a fixed effect summary estimate; 95% confidence intervals (95%CI)

512 (dashed lines) either side will include 95% of studies if no bias is present and the fixed effect assumption (that

513 the true treatment effect is the same in each study) is valid. Solid (red) line of no effect.

514

#### 515 Sensitivity analyses

516 No association was found when dropping the largest pooled analysis by Gaudet et al.<sup>11</sup> for 517 obesity in combined head and neck cancer (RR= 0.82, 95%CI (0.43, 1.56) with evidence again for heterogeneity (I<sup>2</sup> = 65.9%, *P heterogeneity* = 0.087). This lack of effect for obesity was 518 519 consistent across subsites, with results all crossing the null. Similarly, there was no 520 difference in the effect of type 2 diabetes on oral cancer risk when leaving out the other large pooled analysis by Gong et al.<sup>17</sup> (RR= 0.98, 95%CI (0.95, 1.01), with no change in 521 evidence for substantial heterogeneity ( $I^2 = 95.8\%$ , *P heterogeneity* = <0.001). 522 523 524 Discussion

525

This is the most comprehensive and up-to-date systematic review and meta-analysis on this 526

topic, considering the association of metabolic traits on HNC across subsites at a global 527

- 528 population level. Despite observations from individual studies suggesting an association
- 529 between BMI and HNC, no effect was found within any subsite in this study, using random-

- 530 effects meta-analyses (Figure 2). There was also limited evidence of an association for type
- 531 2 diabetes (Figure 3), but perhaps a trend towards increased risk for overall HNC, which is in
- 532 keeping with previous pooled estimates <sup>12,19,20,59</sup>. Conversely, there was evidence of an
- 533 increased HNC risk for both hypertension and dyslipidaemia across subsites, but with fewer
- 534 studies included in these meta-analyses (Figure 4 &

#### **Dyslipidaemia and risk of HNC** 535

- 536 There were only 2 studies available for meta-analysis, both investigating the effect of
- dyslipidaemia on incident laryngeal cancer risk. There was some evidence of an increased 537
- 538 risk association of both low HDL (RR= 1.12, 95%CI (1.07, 1.18)) and high triglyceride levels
- 539 (RR= 1.10, 95%CI (1.05, 1.15)) using a random-effects model (Error! Not a valid bookmark
- 540 self-reference.  $\mathbf{a} - \mathbf{b}$ ). In the low HDL analysis, there was evidence of moderate
- 541 heterogeneity (*P* heterogeneity= 0.103,  $I^2 = 62.5\%$ ), which was not found in the high
- 542 triglycerides analysis (P heterogeneity= 0.319,  $I^2 = 0.0\%$ ) (Error! Not a valid bookmark self-
- 543 reference.  $\mathbf{a} - \mathbf{b}$ ). The results remained similar when using a fixed effects model across all
- 544 sites. These findings were not supported in the single study by Jiang et al.<sup>12</sup> which
- investigated low HDL (RR= 1.01, 95%CI (0.84, 1.22)) and high triglycerides (RR= 0.95, 95%CI 545
- 546 (0.81, 1.10)) on head and neck combined cancer (Table 2).
- 547

548 Figure 5). Furthermore, over 80% of studies were judged to be at 'Very High' or 'High' risk of 549 bias using the ROBINS-E tool (Supplementary Figures 1 - 4), so caution must be exercised 550 when interpreting these results. Of those studies assessed as low risk of bias, their results 551 suggest limited evidence for an effect of obesity, but an increased risk association of type 2 diabetes <sup>12</sup> on HNC risk. Conversely, this was not the case for hypertension and 552 553 dyslipidaemia, where the one study assessed as low risk of bias for these traits did not provide evidence of an effect on HNC risk <sup>12</sup>. Variability in the individual study results may 554 555 exist due to differences in timing of exposure measurement, confounder adjustment, or 556 from other sources of bias.

557

558 An apparent obesity paradox demonstrated in individual studies <sup>55,67</sup> might be explained by

559 BMI as a collider acting as a form of selection bias <sup>68</sup>. While tobacco smoking is correlated

- with obesity, this may be dose dependant and change following smoking cessation <sup>69</sup>. 560
- 561 Furthermore, many HNC patients are more likely to be underweight at presentation,

562 particularly those with alcohol use disorders, often correlated with heavy smoking 563 behaviour. Variability in the results may exist due to differences in timing of the exposure 564 measurement, whereby misclassification of participants into the wrong BMI category could 565 have occurred. This is because around one-third to a half of HNC patients experience between 5 – 10% weight loss during the period prior to diagnosis  $^{70}$ . Obesity may also 566 567 provide additional nutritional reserves giving patients a survival advantage, if for example 568 there was latent tumour progression prior to the baseline diagnosis in these observational 569 studies. There may be issues with measurement error again leading to misclassification in 570 this study, given BMI is simply a function of mass and height and does not specifically 571 indicate metabolically unhealthy adiposity or take into account lean muscle mass. In future, 572 more accurate measures body composition such as bioelectrical impedance or dual-energy X-ray absorptiometry (DEXA) scanning could be used to better differentiate fat mass from 573 574 lean tissue. This study also lacked detail on HPV status or tumour stage, with more 575 advanced stage disease likely resulting in more significant weight loss <sup>71</sup>. Subgroup 576 differences were found across metabolic traits with respect to geographic location. Stronger effects were found for obesity in USA compared with the UK, and for both type 2 diabetes 577 578 and dyslipidaemia in Asian populations compared with the other continents, which is in keeping with global epidemiology <sup>72,73</sup>. Larger subgroup effects were also found when 579 580 patient's self-reported their diagnoses compared to researchers using medical records, 581 suggesting recall bias may be present.

582

583 Strengths and limitations of this study

584 This meta-analysis includes the largest available studies, resulting in a sample size of n= 585 39,002 HNC cases in a total population size of over 84 million. This suggests the study was 586 well powered to detect any association between metabolic traits and HNC, however there 587 were fewer studies for hypertension and dyslipidaemia compared to the other traits. As 588 there were <10 studies in these analysis, a comprehensive assessment of publication or reporting bias could not be made. However, the lack of smaller positive or negative effect 589 590 studies for type 2 diabetes suggests potential publication or reporting bias. Both the obesity 591 and type 2 diabetes funnel plots revealed outlier results. Leaving out the two outlier studies 592 in the obesity meta-analysis had little effect on the overall null finding. Evidence of 593 substantial heterogeneity was present (I<sup>2</sup> values >50%) between studies across all metabolic

594 traits, which increased when combining HNC subsites as would be expected. In particular for 595 type 2 diabetes whereby four out of five outlier studies were in Asian only populations. This 596 could be due to the differences in HNC aetiology in Asia e.g., betel quid chewing. Future 597 work should include meta-analysing studies separately by geographic region or restricting to 598 particular populations, as this appears to be a clear source of heterogeneity. Other forms of 599 bias such as collider, recall and information bias may have been present, as described in the 600 previous section. Despite multivariable adjustment within studies, residual confounding 601 may still exist, given that HNC risk factors, such as smoking, alcohol and socioeconomic 602 status are difficult to fully account for. While we conducted a number of subgroup analyses, 603 there was insufficient data in the included studies to examine the effect of sex. This may 604 have been important as previous analyses have suggested that the effect of type 2 diabetes 605 on HNC was mainly found in females <sup>17</sup>, which may indicate poorer metabolic control, 606 elevated exposure to insulin and subsequent oxidative DNA damage. There were limited 607 data for smoking at specific subsites across the metabolic traits and therefore meta-analysis 608 at this level was not possible. 609 610 Conclusions 611 612 The meta-analysis performed in this study suggested there was limited evidence for an association between obesity or type 2 diabetes and HNC risk. However, there was some 613 614 evidence for increased risk associations with hypertension and dyslipidaemia. These

observational associations are susceptible to confounding, bias and reverse causality and

results must be interpreted with caution given the high risk of bias detected.

- 617
- 618

### 619 Authors' contributions

620

AG and CR jointly contributed to the development of the protocol, and the drafting, writing
and editing of this manuscript. FS contributed to the development of this study and editing
of the manuscript. JH contributed to the development of the search strategy. BM, EG, EV,

RR and JPTH contributed to the development of this study. MG was responsible for
conceptualising this study, drafting and editing this manuscript. All authors contributed to
the development of the search strategy. All authors have approved and contributed to the
final written manuscript.

### 629 Funding statement

630

631 A.G. is a National Institute for Health and Care Research (NIHR) doctoral research fellow (NIHR302605). C.R. is currently supported by a Wellcome Trust GW4-Clinical Academic 632 633 Training PhD Fellowship. F.S. was supported by a Cancer Research UK (C18281/A29019) 634 programme grant (the Integrative Cancer Epidemiology Programme). E.E.V is supported by 635 Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund 636 (WCRF UK), as part of the World Cancer Research Fund International grant programme 637 (IIG 2019 2009). R.C.R. is a de Pass VC research fellow at the University of Bristol (no grant 638 number). J.P.T.H supported by the NIHR Biomedical Research Centre at University Hospitals 639 Bristol and Weston NHS Foundation Trust and the University of Bristol (no grant number), 640 the NIHR Applied Research Collaboration West at University Hospitals Bristol and Weston 641 NHS Foundation Trust (no grant number) and is a National Institute for Health Research 642 (NIHR) Senior Investigator (no grant number). M.G. was supported by a Wellcome Trust 643 GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the 644 Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of Open Access, the author 645 has applied a CC BY public copyright licence to any Author Accepted Manuscript version 646 arising from this submission. The views expressed in this publication are those of the 647 author(s) and not necessarily those of Wellcome, NIHR, the NHS or Department of Health.

648		
649	Compe	eting interests statement
650		
651	None o	declared
652		
653	Patien	t and Public Involvement
654		
655	Patient	ts and/or the public were not involved in the development, conduct or proposed
656	dissem	ination of this systematic review protocol.
657		
658	Word	Count: 1,956 (excluding abstract)
659		
660	Refere	nces
661		
662	1	Office for National Statistics. Data for 1974 onwards: Office for National Statistics.
663		Adult Smoking habits in Great Britain. ,
664		<https: dru<="" healthandsocialcare="" peoplepopulationandcommunity="" td="" www.ons.gov.uk=""></https:>
665		gusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain.> (2020).
666	2	Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and
667		mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for
668		Clinicians, doi: https://doi.org/10.3322/caac.21660 (2021).
669	3	Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nature Reviews
670		Disease Primers <b>6</b> , 92, doi:10.1038/s41572-020-00224-3 (2020).

671	4	Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head
672		and neck squamous cell cancer: A tale of three cancers? Clin Otolaryngol 43, 999-
673		1003, doi:10.1111/coa.13144 (2018).
674	5	World Health Organization (WHO). WHO European Regional Obesity Report 2022.
675		[Internet] [cited 2022 Jun 06],
676		<https: 10665="" 353747="" 9789289057738-<="" apps.who.int="" bitstream="" handle="" iris="" td=""></https:>
677		<u>eng.pdf</u> > (2022).
678	6	Arnold, M. et al. Global burden of cancer attributable to high body-mass index in
679		2012: a population-based study. Lancet Oncol 16, 36-46, doi:10.1016/s1470-
680		2045(14)71123-4 (2015).
681	7	Tran, K. B. <i>et al.</i> The global burden of cancer attributable to risk factors, 2010-2019:
682		a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 400,
683		563-591, doi:10.1016/S0140-6736(22)01438-6 (2022).
684	8	Davey, R. C. The obesity epidemic: too much food for thought? British Journal of
685		Sports Medicine <b>38</b> , 360-363, doi:10.1136/bjsm.2003.007443 (2004).
686	9	Wotton, C. J., Yeates, D. G. & Goldacre, M. J. Cancer in patients admitted to hospital
687		with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia
688		<b>54</b> , 527-534, doi:10.1007/s00125-010-1987-2 (2011).
689	10	Stott-Miller, M. et al. History of diabetes and risk of head and neck cancer: a pooled
690		analysis from the international head and neck cancer epidemiology consortium.
691		<i>Cancer Epidemiol Biomarkers Prev</i> <b>21</b> , 294-304, doi:10.1158/1055-9965.EPI-11-0590
692		(2012).
693	11	Gaudet, M. M. et al. Anthropometry and head and neck cancer:a pooled analysis of
694		cohort data. Int J Epidemiol 44, 673-681, doi: https://dx.doi.org/10.1093/ije/dyv059
695		(2015).

696	12	Jiang, H. et al. The effect of metabolic syndrome on head and neck cancer incidence
697		risk: a population-based prospective cohort study. Cancer & metabolism 9, 25,
698		doi: <u>https://dx.doi.org/10.1186/s40170-021-00261-w</u> (2021).
699	13	Diaz, Y. et al. Body mass index and waist circumference in relation to the risk of 26
700		types of cancer: a prospective cohort study of 3.5 million adults in Spain. BMC
701		Medicine <b>19</b> , 10, doi: <u>http://dx.doi.org/10.1186/s12916-020-01877-3</u> (2021).
702	14	Cao, Z. et al. Association of obesity status and metabolic syndrome with site-specific
703		cancers: a population-based cohort study. Brit J Cancer <b>123</b> , 1336-1344,
704		doi: <u>http://dx.doi.org/10.1038/s41416-020-1012-6</u> (2020).
705	15	Gribsholt, S. B. <i>et al.</i> Hospital-diagnosed overweight and obesity related to cancer
706		risk: a 40-year Danish cohort study. Journal of Internal Medicine 287, 435-447,
707		doi: <u>http://dx.doi.org/10.1111/joim.13013</u> (2020).
708	16	Ward, H. A. et al. Measured Adiposity in Relation to Head and Neck Cancer Risk in
709		the European Prospective Investigation into Cancer and Nutrition. Cancer
710		epidemiology, biomarkers & prevention : a publication of the American Association
711		for Cancer Research, cosponsored by the American Society of Preventive Oncology
712		<b>26</b> , 895-904, doi: <u>https://dx.doi.org/10.1158/1055-9965.EPI-16-0886</u> (2017).
713	17	Gong, Y., Wei, B., Yu, L. & Pan, W. Type 2 diabetes mellitus and risk of oral cancer
714		and precancerous lesions: a meta-analysis of observational studies. Oral oncology
715		<b>51</b> , 332-340, doi: <u>https://dx.doi.org/10.1016/j.oraloncology.2015.01.003</u> (2015).
716	18	Saarela, K. et al. Cancer incidence among Finnish people with type 2 diabetes during
717		1989-2014. Eur J Epidemiol <b>34</b> , 259-265, doi: <u>https://dx.doi.org/10.1007/s10654-018-</u>
718		<u>0438-0</u> (2019).
719	19	Kim, HB., Kim, GJ., Han, Kd. & Joo, YH. Changes in metabolic syndrome status
720		and risk of laryngeal cancer: A nationwide cohort study. PLoS ONE 16, e0252872-
721		e0252872, doi: <u>http://dx.doi.org/10.1371/journal.pone.0252872</u> (2021).

722	20	Kim, SY., Han, Kd. & Joo, YH. Metabolic Syndrome and Incidence of Laryngeal
723		Cancer: A Nationwide Cohort Study. Scientific reports 9, 667,
724		doi: <u>https://dx.doi.org/10.1038/s41598-018-37061-0</u> (2019).
725	21	Stocks, T. et al. Blood pressure and risk of cancer incidence and mortality in the
726		Metabolic Syndrome and Cancer Project. Hypertension 59, 802-810,
727		doi: <u>https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.189258</u> (2012).
728	22	Christakoudi, S. et al. Blood pressure and risk of cancer in the European Prospective
729		Investigation into Cancer and Nutrition. Int J Cancer 146, 2680-2693,
730		doi: <u>http://dx.doi.org/10.1002/ijc.32576</u> (2020).
731	23	Seo, JH., Kim, YD., Park, CS., Han, Kd. & Joo, YH. Hypertension is associated
732		with oral, laryngeal, and esophageal cancer: a nationwide population-based study.
733		Scientific reports 10, 10291, doi: <u>https://dx.doi.org/10.1038/s41598-020-67329-3</u>
734		(2020).
735	24	Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in patients
736		with diabetes mellitus: a retrospective cohort study in Taiwan. JAMA Otolaryngol
737		Head Neck Surg 140, 746-753, doi:10.1001/jamaoto.2014.1258 (2014).
738	25	Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat Rev
739		<i>Cancer</i> <b>4</b> , 891-899, doi:10.1038/nrc1478 (2004).
740	26	Warburg, O., Wind, F. & Negelein, E. The metabolism fo tumors in the body. <i>J Gen</i>
741		<i>Physiol</i> <b>8</b> , 519-530, doi:10.1085/jgp.8.6.519 (1927).
742	27	Scully, T., Ettela, A., LeRoith, D. & Gallagher, E. J. Obesity, Type 2 Diabetes, and
743		Cancer Risk. Frontiers in Oncology 10, doi:10.3389/fonc.2020.615375 (2021).
744	28	Wang, W., Bai, L., Li, W. & Cui, J. The Lipid Metabolic Landscape of Cancers and New
745		Therapeutic Perspectives. Frontiers in Oncology 10, doi:10.3389/fonc.2020.605154
746		(2020).

747	29	Covidence. Covidence systematic review software, Veritas Health Innovation,
748		Melbourne, Australia. [Internet] [cited 2022 July 29], < <u>https://www.covidence.org/</u> >
749		(2022).

- Gormley, A. *et al.* Metabolic disorders and the risk of head and neck cancer: a
  protocol for a systematic review and meta-analysis. *BMJ Open* 12, e058392,
  doi:10.1136/bmjopen-2021-058392 (2022).
- Liberati, A. *et al.* The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and
  elaboration. *BMJ* **339**, b2700, doi:10.1136/bmj.b2700 (2009).
- Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes
  mellitus and its complications. Part 1: diagnosis and classification of diabetes
  mellitus provisional report of a WHO consultation. *Diabet Med* 15, 539-553,
  doi:10.1002/(sici)1096-9136(199807)15:7<539::Aid-dia668>3.0.Co;2-s (1998).
- Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome--a new worldwide
  definition. *Lancet* 366, 1059-1062, doi:10.1016/s0140-6736(05)67402-8 (2005).
- 762 34 National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the
  763 National Cholesterol Education Program (NCEP) Expert Panel on Detection,
  764 Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
- 765 Panel III) final report. *Circulation* **106**, 3143-3421 (2002).
- World Health Organization (WHO). *Obesity and overweight [Internet] [cited 2022 July 26]*, <<u>https://www.who.int/news-room/fact-sheets/detail/obesity-and-</u>
  <u>overweight</u>> (2021).
- 36 World Health Organization (WHO). *Definition and Diagnosis of Diabetes Mellitus and*770 *Intermediate Hyperglycaemia [Internet] [cited 2022 July 26],*
- 771 <<u>https://www.diabetes.org.uk/resources-s3/2017-</u>
- 772 <u>09/Definition\_and\_diagnosis1111.pdf</u>> (2006).

### 773 37 World Health Organization (WHO). Use of Glycated Haemoglobin (HbA1c) in the

- 774 Diagnosis of Diabetes Mellitus [Internet] [cited 2022 July 26],
- 775 <<u>https://www.diabetes.org.uk/resources-s3/2017-</u>
- 776 <u>09/Definition and diagnosis1111.pdf</u>> (2011).
- World Health Organization (WHO). *Hypertension [Internet] [cited 2022 July 26]*,
  <a href="https://www.who.int/news-room/fact-sheets/detail/hypertension.>">https://www.who.int/news-room/fact-sheets/detail/hypertension.></a> (2021).
- British Medical Journal. *Hypercholesterolemia* [Internet] [cited 2022 July 26],
   <a href="https://bestpractice.bmj.com/topics/en-us/170">https://bestpractice.bmj.com/topics/en-us/170</a> (2019).
- World Health Organization (WHO). World Health Organization (WHO): International
  statistical classification of diseases and related health problems (10th ed.) [Internet]
  [cited 2022 July 26]. <a href="https://icd.who.int/browse10/2019/en#/">https://icd.who.int/browse10/2019/en#/</a>> (2016).
- 784 41 ROBINS-E Development Group (Higgins J, M. R., Rooney A, Taylor K, Thayer K, Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn 785 786 B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L, 787 Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, 788 Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk Of 789 790 Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 1 June 791 2022., <https://www.riskofbias.info/welcome/robins-e-tool]> (2022).
- ROBINS-E Development Group, H. J., Morgan R, Rooney A, Taylor K, Thayer K, Silva R,
  Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn
  B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L,
  Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J,
  Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T,
  Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J. *Risk Of*
- 798 Bias In Non-randomized Studies of Exposure (ROBINS-E) [Internet] [cited 2022 July
- 799 29], <<u>https://www.riskofbias.info/welcome/robins-e-tool</u>.> (2022).

800	43	DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-
801		188, doi:10.1016/0197-2456(86)90046-2 (1986).
802	44	Sterne, J. A. C. et al. Recommendations for examining and interpreting funnel plot
803		asymmetry in meta-analyses of randomised controlled trials. BMJ 343, d4002,
804		doi:10.1136/bmj.d4002 (2011).
805	45	Andreotti, G. et al. Body mass index, agricultural pesticide use, and cancer incidence
806		in the Agricultural Health Study cohort. <i>Cancer Causes Control</i> <b>21</b> , 1759-1775,
807		doi:10.1007/s10552-010-9603-9 (2010).
000	16	Gaudat M. M. at al. Prochastivo studios of body mass index with boad and pack
000	40	Gaudel, W. W. et al. Prospective studies of body mass index with head and heck
809		cancer incidence and mortality. <i>Cancer epidemiology, biomarkers &amp; prevention</i> <b>21</b> ,
810		497-503, doi: <u>https://dx.doi.org/10.1158/1055-9965.EPI-11-0935</u> (2012).
811	47	Hashibe, M. et al. Tobacco, alcohol, body mass index, physical activity, and the risk of
812		head and neck cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort.
813		Head & neck <b>35</b> , 914-922, doi: <u>https://dx.doi.org/10.1002/hed.23052</u> (2013).
814	48	Etemadi, A. <i>et al.</i> A prospective cohort study of body size and risk of head and neck
815		cancers in the NIH-AARP diet and health study. Cancer epidemiology, biomarkers &
816		prevention <b>23</b> , 2422-2429, doi: <u>https://dx.doi.org/10.1158/1055-9965.EPI-14-0709-T</u>
817		(2014).
818	49	Hialgrim, H. <i>et al.</i> Cancer and diabetesa follow-up study of two population-based
819		cohorts of diabetic patients. J Intern Med <b>241</b> , 471-475, doi:10.1111/j.1365-
820		2796.1997.tb00004.x (1997).
	_	
821	50	Wideroff, L. et al. Cancer incidence in a population-based cohort of patients
822		hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89, 1360-1365,
823		doi:10.1093/jnci/89.18.1360 (1997).

824	51	Stocks, T. et al. Blood glucose and risk of incident and fatal cancer in the metabolic
825		syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med
826		<b>6</b> , e1000201, doi:10.1371/journal.pmed.1000201 (2009).
827	52	Tseng, CH. Oral cancer in Taiwan: is diabetes a risk factor? Clinical oral
828		investigations <b>17</b> , 1357-1364, doi: <u>https://dx.doi.org/10.1007/s00784-012-0820-3</u>
829		(2013).
830	53	Lai, G. Y., Park, Y., Hartge, P., Hollenbeck, A. R. & Freedman, N. D. The association
831		between self-reported diabetes and cancer incidence in the NIH-AARP Diet and
832		Health Study. J Clin Endocrinol Metab 98, E497-502, doi:10.1210/jc.2012-3335
833		(2013).
834	54	Samanic, C., Chow, W. H., Gridley, G., Jarvholm, B. & Fraumeni, J. F., Jr. Relation of
835		body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17,
836		901-909, doi:10.1007/s10552-006-0023-9 (2006).
837	55	Bhaskaran, K., Douglas, I., Forbes, H. & Smeeth, L. Associations between body mass
838		index and a range of cancers: A population-based study within the UK Clinical
839		Practice Research Datalink. Eur J Epidemiol 28, S97,
840		doi: <u>http://dx.doi.org/10.1007/s10654-013-9820-0</u> (2013).
841	56	Maasland, D. H., van den Brandt, P. A., Kremer, B. & Schouten, L. J. Body mass index
842		and risk of subtypes of head-neck cancer: the Netherlands Cohort Study. Sci Rep 5,
843		17744, doi:10.1038/srep17744 (2015).
844	57	Chodick, G. et al. Diabetes and risk of incident cancer: A large population-based
845		cohort study in Israel. Cancer Causes and Control 21, 879-887,
846		doi: <u>http://dx.doi.org/10.1007/s10552-010-9515-8</u> (2010).
847	58	Atchison, E. A., Gridley, G., Carreon, J. D., Leitzmann, M. F. & McGlynn, K. A. Risk of
848		cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128, 635-643,
849		doi: <u>https://dx.doi.org/10.1002/ijc.25362</u> (2011).

850	59	Lo, S. F. et al. Modest increase in risk of specific types of cancer types in type 2
851		diabetes mellitus patients. Int J Cancer 132, 182-188,
852		doi: <u>http://dx.doi.org/10.1002/ijc.27597</u> (2013).
853	60	Walker, J. J. <i>et al.</i> Type 2 diabetes, socioeconomic status and risk of cancer in
854		Scotland 2001-2007, <i>Diabetologia</i> <b>56</b> , 1712-1715,
855		doi: <u>http://dx.doi.org/10.1007/s00125-013-2937-6</u> (2013).
856	61	Nakamura, K. <i>et al.</i> Diabetes mellitus and risk of cancer in Takayama: a population-
857	01	hased prospective cohort study in Japan <i>Cancer Sci</i> <b>104</b> 1362-1367
858		doi:10.1111/cas.12235 (2013).
859	62	Lin, C. C. <i>et al.</i> Cancer risks among patients with type 2 diabetes: A 10-year follow-up
860		study of a nationwide population-based cohort in Taiwan. <i>BMC Cancer</i> <b>14</b> , 381,
861		doi: <u>http://dx.doi.org/10.1186/1471-2407-14-381</u> (2014).
862	63	He, X., Shi, L. & Wu, J. Retrospective database analysis of cancer risk in patients with
863		type 2 diabetes mellitus in China. Current Medical Research and Opinion 34, 1089-
864		1098, doi: <u>http://dx.doi.org/10.1080/03007995.2017.1421527</u> (2018).
865	64	Qi, J. et al. Cancer risk among patients with type 2 diabetes: A real-world study in
866		Shanghai, China. <i>J Diabetes</i> <b>11</b> , 878-883, doi:10.1111/1753-0407.12926 (2019).
867	65	Chyou, P. H., Nomura, A. M., Stemmermann, G. N. & Kato, I. Prospective study of
868		serum cholesterol and site-specific cancers. Journal of clinical epidemiology 45, 287-
869		292 (1992).
870	66	Gaudet, M. M. et al. Anthropometry and head and neck cancer:a pooled analysis of
871		cohort data. Int J Epidemiol <b>44</b> , 673-681, doi:10.1093/ije/dyv059 (2015).
872	67	Chen, Y. et al. Body mass index and the risk of head and neck cancer in the Chinese
873		population. Cancer Epidemiol 60, 208-215, doi:10.1016/j.canep.2019.04.008 (2019).

874 68 Holmberg, M. J. & Andersen, L. W. Collider Bias. JAMA 327, 1282-1283,

doi:10.1001/jama.2022.1820 (2022).

- B76 69 Dare, S., Mackay, D. F. & Pell, J. P. Relationship between smoking and obesity: a
  cross-sectional study of 499,504 middle-aged adults in the UK general population.
  PLoS One 10, e0123579, doi:10.1371/journal.pone.0123579 (2015).
- Jager-Wittenaar, H. *et al.* Critical weight loss in head and neck cancer--prevalence
  and risk factors at diagnosis: an explorative study. *Support Care Cancer* 15, 10451050, doi:10.1007/s00520-006-0212-9 (2007).
- Strulov Shachar, S. & Williams, G. R. The Obesity Paradox in Cancer-Moving Beyond
  BMI. *Cancer Epidemiol Biomarkers Prev* 26, 13-16, doi:10.1158/1055-9965.Epi-160439 (2017).
- Saeedi, P. *et al.* Global and regional diabetes prevalence estimates for 2019 and
  projections for 2030 and 2045: Results from the International Diabetes Federation
  Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* **157**, 107843,
  doi:10.1016/j.diabres.2019.107843 (2019).
- 889 73 Blüher, M. Obesity: global epidemiology and pathogenesis. *Nature Reviews* 890 *Endocrinology* 15, 288-298, doi:10.1038/s41574-019-0176-8 (2019).

# Supplementary information

Supplementary Appendix 1 Systematic review protocol

Supplementary Appendix 2 PRISMA checklist

### Supplementary Table 1 Search strategy

1 exp "HEAD AND NECK NEOPLASMS"/ 2

("head and neck cancer" or "oral cancer").ti,ab.

```
3
```

((lip or lips or mouth or gums or palatal or palate or gingiva\* or buccal or cheek\* or tongue or lingual or glosso\* or laryn\* or "vocal chord\*" or "vocal cord\*" or "vocal fold\*" or subglottic or supraglottic or hypopharyn\* or hypo-pharyn\* or epiglottis or arytenoids or aryepiglottic or throat or oropharyn\* or oropharyn\* or tonsil\* or pharyn\* or otolaryn\* or jaw or mandib\* or maxill\*) adj3 (cancer\* or carcinoma\* or neoplasm\* or tumour\* or tumor\* or squamous or lymphoma\* or HPV or "human papillomavirus")).ti,ab.

```
1 or 2 or 3
5
```

exp DYSLIPIDEMIAS/

```
6
```

(dyslipidaemia or dyslipidemia or lipolysis or hypercholesterolemia or hypercholesterolaemia or "low density lipoprotein" or "apolipoprotein" or cholesterol or LDL or triglycerides or statin\* or ezetimibe or "HMG-CoA" or "reductase inhibitor\*" or "HMGCR" or "hydroxymethylglutaryl coa reductases" or "NPC1L1" or "PCSK9" or "CETP" or "LDLR" or atorvastatin or fluvastatin or lovastatin or pitavastatin or pravastatin or rosuvastatin or simvastatin or (lipid\* adj2 (metaboli\* or medicat\* or drug\* or lower\* or reduc\* or decreas\*))).ti,ab.

exp DIABETES MELLITUS/

```
9
```

(Diabet\* or insulin or "insulin resistance" or hyperglycaemia or hypoglycaemia or hyperglycemia or hypoglycemia or hypertension or metformin or glucagon or "hypoglycaemic agent\*" or HbA1 or HbA1 or (glucose adj2 (impair\* or tolerance or intolerance)) or IGT or glycogenolysis or gluconeogenesis or GDF?15 or gliflozins or SGLT2 or sulphonylurea\* or meglitinide\* or thiazolidinediones or "DPP-4 inhibitor\*" or "GLP-1 receptor agonist\*").ti,ab.

10

8 or 9

11

exp METABOLIC SYNDROME/

12

(metabolic syndrome or "dyresgulated metaboli\*" or obesity or obes\* or "abdominal obes\*" or (fat or fatty or fats) or "body weight" or adipos\* or (weight adj2 gain\*) or overeat\* or bariatric or (over adj2 eat) or "body mass index\*" or BMI).ti,ab.

13 11 or 12 14 7 or 10 or 13 15 4 and 14 16 exp RISK/ 17 (risk\* or inciden\* or prevalen\*).ti,ab. 18 16 or 17 19 15 and 18 Supplementary Table 2 Modified search strategy

1 HEAD AND NECK CANCER 2 AND 3 CHOLESTEROL 4 OR 5 DIABETES 6 OR 7 METABOLIC SYNDROME 8 OR 9 OBESITY

**Supplementary Table 3** Subgroup analyses for the association of metabolic disorders and risk of head and neck cancer

Characteristic	Subgroup	Effect size (RR, 95% Cl)	P heterogeneity	l <sup>2</sup> (%)	P difference between groups
Obesity					
Age	<50	0.95 (0.87 – 1.04)	0.567	0	0.396
	>50	1.05 (0.85 - 1.29)	0.119	43.0	
Geographiclocation	Asian	NA	NA	NA	
	European	0.97 (0.90 - 1.04)	0.613	0	0.007
	USA	1.40 (1.08 - 1.81)	NA (single	NA	
			study)		
Year of publication	After 2010	0.99 (0.90 - 1.08)	0.183	22.9	0.855
	Before 2010	0.94 (0.57 - 1.56)	NA (single	NA	
			study)		
Methods of exposure assessment	MR	0.94 (0.86 - 1.04)	0.543	0	0.011
	SR	0.63 (0.38 - 1.06)	0.802	0	
	Measu red at	1.02 (0.91 - 1.15)	0.586	0	
	baseline				
	Combination	1.40 (1.08 - 1.81)	NA (single	NA	
			study)		
Adjustment for age, sex, smoking and	Yes	1.00 (0.89 - 1.12)	0.433	0.1	0.816
alcohol as confounders	No	0.98 (0.87 - 1.11)	0.088	45.6	
Length of follow-up	<10 years	1.00 (0.91 - 1.10)	0.125	38.3	0.697
	≥10 years	0.93 (0.75 - 1.16)	0.357	9.3	
Number of cancer cases	<50	0.85 (0.67 - 1.06)	0.518	0	0.323
	≥50	1.00 (0.91 - 1.10)	0.125	38.3	
Type 2 diabetes mellitus					
Age	<50	1.09 (1.01 - 1.17)	<0.0001	74.7	0.937
	>50	1.09 (0.96 - 1.25)	<0.0001	94.2	
Geographiclocation	Asian	1.23 (1.13 - 1.33)	<0.0001	78.6	<0.0001
	European	1.00 (0.90 - 1.12)	0.001	68.1	

	USA	0.81 (0.72 - 0.90)	0.002	89.1	
Year of publication	After 2010	1.10 (1.00 - 1.20)	<0.0001	93	N
	Before 2010	NA	NA	NA	
Methods of exposure assessment	MR	1.05 (0.93 - 1.18)	<0.0001	93.3	0.08
	SR	NA	NA	NA	
	Measured at	1.12 (1.06 - 1.19)	NA (single	NA	
	baseline		study)		
	Combination	1.19 (1.13 - 1.25)	0.343	11.3	
Adjustment for age, sex, smoking and	Yes	1.15 (1.10 - 1.20)	0.524	0	0.28
alcohol as confounders					
	No	1.07 (0.96 - 1.20)	<0.0001	93.7	
Length of follow-up	<10 years	1.12 (1.04 - 1.21)	0.003	61.3	0.83
	≥10 years	1.11 (0.97 - 1.26)	<0.0001	95	
Number of cancer cases	<50	1.08 (0.84 - 1.38)	0.003	65.5	0.82
	≥50	1.11 (1.01 -1.23)	<0.0001	95.3	
Hypertension					
Age	<50	1.16 (1.08 - 1.25)	0.129	47.1	0.98
	>50	1.16 (1.08 - 1.24)	0.155	37.7	
Geographic location	Asian	1.14 (1.09 - 1.20)	0.205	34.5	0.5
	European	1.18 (1.07 - 1.30)	0.156	37.6	
	USA	NA	NA	NA	
Year of publication	After 2010	1.16 (1.11 - 1.21)	0.133	34.3	N
	Before 2010	NA	NA	NA	
Methods of exposure assessment	MR	NA	NA	NA	N
	SR	NA	NA	NA	
	Measu red at	1.16 (1.11 - 1.21)	0.133	34.4	
	baseline				
	Combination	NA	NA	NA	
Adjustment for age, sex, smoking and	Yes	1.15 (1.10 - 1.19)	0.287	19.1	0.62
alcohol as confounders					
	No	1.19 (0.96 - 1.48)	0.071	69.3	

	≥10 years	1.14 (1.09 - 1.19)	0.175	36.9	
	-E 0		NA	NIA	NIA
Number of cancer cases	<50		NA 	NA 	NA
	≥50 	1.16 (1.11 - 1.21)	0.113	34.3	
Dyslipidaemia					
Age	<50	1.12 (1.08 - 1.16)	0.191	36.9	0.047
	>50	0.94 (0.80 - 1.11)	0.251	26.7	
Geographic location	Asian	1.12 (1.08 - 1.16)	0.191	36.9	0.006
	European	0.97 (0.87 - 1.10)	0.619	0	
	USA	0.45 (0.21 - 0.98)	0.692	0	
Year of publication	After 2010	1.10 (1.06 - 1.15)	0.063	52.3	0.024
	Before 2010	0.45 (0.21 - 0.98)	0.692	0	
Methods of exposure assessment	MR	NA	NA	NA	NA
	SR	NA	NA	NA	
	Measu red at	1.09 (1.04 - 1.15)	0.026	56	
	baseline				
	Combination	NA	NA	NA	
Adjustment for age, sex, smoking and	Yes	1.10 (1.06 - 1.15)	0.063	52.3	0.024
alcohol as confounders					
	No	0.45 (0.21 - 0.98)	0.692	0	
Length of follow-up	<10 years	1.10 (1.06 - 1.15)	0.063	52.3	0.024
J	≥10 years	0.45 (0.21 - 0.98)	0.692	0	5.021
Number of cancer cases	<50	0.45/0.21 - 0.98	0 692	0	0.024
Number of Carter Cases	<u>\</u>	1.10(1.00 1.15)	0.092	522	0.024
	250	1.10(1.06 - 1.15)	0.063	52.3	

**Supplementary Figures 1 – 4** Risk of bias assessments for each metabolic trait using the ROBINS-E tool

#### Risk of bias domains Overall D1 D2 D3 D4 D5 D6 D7 Bhaskaran, 2014 + + (-)+ + X + + -Cao, 2020 + +++ ++ + Gaudet, 2015 ---) + + + + Gribsholt, 2020 ++ + + X Study + + Jiang, 2021 + + + + + + + + Maasland, 2015 (-) + + + -Samanic, 2006 ++(+)++х х Ward, 2017 + -+ -+ + Domains: D1: Bias due to confounding. D2: Bias arising from measurement of the exposure. Judgement High D2: bias ansing from measurement of the exposure. D3: Bias in selection of participants into the study (or into the analysis). D4: Bias due to post-exposure interventions. D5: Bias due to missing data. D6: Bias arising from measurement of the outcome. D7: Bias in selection of the reported result. Some concerns + Low

### Supplementary Figure 1 Obesity

		Risk of bias domains									
		D1	D2	D3	D4	D5	D6	D7	Overall		
Study	Atchison, 2011	×	+	+	+	+	+	+	×		
	Chodick, 2010	×	+	+	+	×	+	+	×		
	Gong, 2015	×	+	+	+	×	+	+	×		
	He, 2018	×	+	+	+	×	+	+	×		
	Jiang, 2021	+	+	+	+	+	+	+	+		
	Kim, 2019	-	+	+	+	×	+	+	×		
	Kim, 2021	-	+	+	+	×	+	+	×		
	Lin, 2014		+	+	+	×	+	+	×		
	Lo, 2013	×	+	+	+	+	+	+	×		
	Nakamura, 2013	×	+	+	+	×	+	+	×		
	Qi, 2019	×	+	+	+	×	+	+	×		
	Saarela, 2019		+	+	+	+	+	+			
	Seo, 2020	-	+	+	+	×	+	+	×		
	Tseng, 2014	×	+	+	+	×	+	+	×		
	Walker, 2013	×	+	+	+	×	+	+	×		
	Domains:						Judg	Judgement			
D1: Bias due to contounding. D2: Bias arising from measurement of the exposure. D3: Bias in selection of participants into the study (or into the analysis).								Very high			
							8	High			

- Some concerns 🕂 Low

D3. bias in selection of participants into the study (of D4: Bias due to post-exposure interventions.
D5: Bias due to missing data.
D6: Bias arising from measurement of the outcome.
D7: Bias in selection of the reported result.

## Supplementary Figure 3 Hypertension



### Supplementary Figure 4 Dyslipidaemia

